| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
7,557 |
5,920 |
$628K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,886 |
3,777 |
$606K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
4,590 |
3,674 |
$600K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
15,405 |
5,840 |
$466K |
| 90837 |
Psychotherapy, 53 minutes with patient |
2,451 |
925 |
$344K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,244 |
2,704 |
$143K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
1,636 |
1,289 |
$142K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
8,121 |
7,690 |
$139K |
| 99223 |
Prolong inpt eval add15 m |
1,261 |
1,168 |
$139K |
| 99233 |
Prolong inpt eval add15 m |
2,191 |
957 |
$85K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
1,850 |
1,638 |
$79K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
662 |
456 |
$46K |
| 90791 |
Psychiatric diagnostic evaluation |
210 |
203 |
$29K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
638 |
442 |
$25K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
631 |
431 |
$15K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
664 |
456 |
$14K |
| 99234 |
|
70 |
48 |
$5K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
178 |
171 |
$5K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
63 |
27 |
$5K |
| 99305 |
|
174 |
165 |
$4K |
| G0425 |
Telehealth consultation, emergency department or initial inpatient, typically 30 minutes communicating with the patient via telehealth |
44 |
26 |
$4K |
| 86480 |
|
26 |
25 |
$1K |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
43 |
26 |
$474.15 |
| 86803 |
|
26 |
25 |
$394.42 |
| G2010 |
Remote evaluation of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment |
45 |
28 |
$345.41 |
| 80053 |
Comprehensive metabolic panel |
26 |
25 |
$242.32 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
26 |
25 |
$134.42 |
| 86592 |
|
26 |
25 |
$93.60 |
| 99406 |
|
12 |
12 |
$74.69 |
| 99000 |
|
420 |
212 |
$70.38 |